• InterView
• Restoring confidence post-Invossa incident was my priority
• by Kim, Jin-Gu Jan 10, 2024 05:42am

• Opinion
• [Reporter’s View] Be generous and provide tangible benefits
• by Eo, Yun-Ho Jan 10, 2024 05:42am

• Policy
• Will Enhertu be discussed in this year’s 1st DREC meeting?
• by Lee, Tak-Sun Jan 10, 2024 05:42am

• Company
• K-pharma advances in new Alzheimer’s drug discovery
• by Jan 9, 2024 05:50am

• Company
• GC Biopharma says its ‘Shingrix vaccine shows effect in P2T
• by Lee, Seok-Jun Jan 9, 2024 05:49am

• Policy
• Data Exclusivity Bill for IMDs may soon be legislated
• by Lee, Jeong-Hwan Jan 9, 2024 05:49am

• InterView
• ‘RCC treatment should reflect international guidelines’
• by Son, Hyung-Min Jan 9, 2024 05:49am

• Company
• Recent tech export deals boast record-high upfront payments
• by Chon, Seung-Hyun Jan 9, 2024 05:49am

• Company
• K-pharma to participate in J.P. Morgan Healthcare Conference
• by Jan 8, 2024 06:09am

• Company
• LG Chem transfers its rare obesity drug rights for KRW 130B
• by Kim, Jin-Gu Jan 8, 2024 06:09am